History, Present Situation, and Prospect of Simultaneous Pancreas and Kidney Trans-plantation in Treatment of Diabetes_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 FENGLei ,  XUMing-qing.

Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China;

Corresponding author：

XUMing-qing., Email: xumingqing0018@163.com

Keywords：

Diabetes; Simultaneous pancreas and kidney transplantation; History; Current situation; Prospect

DOI：

10.7507/1007-9424.20150399

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To do a brief introduction and prospects for simultaneous pancreas and kidney transplanta-tion from aspects of recipient screening, choice of operative method, prognosis, quality of life, and complications. Method Domestic and international literatures were collected to summary the effect, prognosis, and the latest progress of simultaneous pancreas and kidney transplantation in the treatment of diabetes. Results As a kind of mature treatment of diabetic with end-stage renal disease, simultaneous pancreas and kidney transplantation had been carried out in most transplantation centers around the world, it had the definite therapeutic effect and controllable side effects, the life quality of posttransplantation patients would be improved notably. However, the screen of transplantation patient, the selection of transplantation operation, and the postoperative immunosuppressive protocols had not yet been reached a consensus. Conclusions Simultaneous pancreas and kidney transplantation is the most effective treatment for type 1 diabetes patients with end-stage renal disease, it provides a more feasible and more physiological way for the secretion of insulin. Although the patient has to undergo a major operation and take some risk, simultaneous pancreas and kidney transplantation still improves the patient's survival rate and the quality of life, and reduces the incidence of complications related to diabetes. Based on the above reasons, simultaneous pancreas and kidney transplantation should be a preferred treatment for all eligible patients.

Citation： FENGLei, XUMing-qing.. History, Present Situation, and Prospect of Simultaneous Pancreas and Kidney Trans-plantation in Treatment of Diabetes. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(12): 1535-1542. doi: 10.7507/1007-9424.20150399 Copy

1.	The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329(14): 977-986.
2.	Gross JL, De Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care, 2005, 28(1): 164-176.
3.	Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery, 1967, 61(6): 827-837.
4.	Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival proba-bilities for dialysis patients vs cadaveric renal transplant recipients. JAMA, 1993, 270(11): 1339-1343.
5.	Lindahl JP, Hartmann A, Horneland R, et al. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease. Diabetologia, 2013, 56(6): 1364-1371.
6.	Sollinger HW, Odorico JS, Becker YT, et al. One thousand simul-taneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg, 2009, 250: 618-630.
7.	Stratta RJ, Shokouh-Amiri MH, Egidi MF, et al. Long-term experi-ence with simultaneous kidney-pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetil-based immunosuppression. Clin Transplant, 2003, 17 Suppl 9: 69-77.
8.	Kandaswamy R, Stock PG, Skeans MA, et al. OPTN/SRTR 2011 Annual Data Report: pancreas. Am J Transplant, 2013, 13 Suppl 1: 47-72.
9.	Gruessner AC. 2011 update on pancreas transplantation: compreh-ensive trend analysis of 25 000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry(IPTR). Rev Diabet Stud, 2011, 8(1): 6-16.
10.	Stratta RJ. Mortality after vascularized pancreas transplantation. Surgery, 1998, 124(4): 823-830.
11.	Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States(US) and non-US cases as reported to the United Network for Organ Sharing(UNOS) and the International Pancreas Transplant Registry(IPTR) as of June 2004. Clin Transplant, 2005, 19(4): 433-455.
12.	Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1 000 pancreas transplants at a single institution. Ann Surg, 2001, 233(4): 463-501.
13.	American Diabetes Association. Pancreas transplantation for patients with type 1 diabetes. Diabetes Care, 2000, 23(1): 117.
14.	Fourtounas C. Transplant options for patients with type 2 diabetes and chronic kidney disease. World J Transplant, 2014, 4(2): 102-110.
15.	Israni AK, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2012 annual data report: pancreas. Am J Transplant, 2014, 14(Suppl 1): 45-68.
16.	Becker BN, Becker YT, Odorico JS, et al. Simultaneous pancreas-kidney and pancreas transplantation. Minerva Urol Nefrol, 2002, 54(4): 213-226.
17.	Schulz T, Schenker P, Flecken M, et al. Donors with a maximum body weight of 50 kg for simultaneous pancreas-kidney transplanta-tion. Transplant Proc, 2005, 37(2): 1268-1270.
18.	Gores PF, Gillingham KJ, Dunn DL, et al. Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience. Ann Surg, 1992, 215(3): 217-230.
19.	Knight RJ, Bodian C, Rodriguez-Laiz G, et al. Risk factors for intra-abdominal infection after pancreas transplantation. Am J Surg, 2000, 179(2): 99-102.
20.	Gruessner RW. Crossmatch positivity and ABO incompatibility//Gruessner RW, Sutherland DE, eds. Transplantation of the pancreas. New York: Springer, 2004: 398-403.
21.	Odorico JS, Voss B, Munoz Del Rio A, et al. Kidney function after solitary pancreas transplantation. Transplant Proc, 2008, 40(2): 513-515.
22.	Sollinger HW, Cook K, Kamps D, et al. Clinical and experimental experience with pancreaticocystostomy for exocrine pancreatic drainage in pancreas transplantation. Transplant Proc, 1984, 16(3): 749-751.
23.	Black PC, Plaskon LA, Miller J, et al. Cystoenteric conversion and reduction cystoplasty for treatment of bladder dysfunction after pancreas transplantation. J Urol, 2003, 170(5): 1913-1917.
24.	Sollinger HW, Odorico JS, Knechtle SJ, et al. Experience with 500 simultaneous pancreas-kidney transplants. Ann Surg, 1998, 228(3): 284-296.
25.	Sollinger HW, Sasaki TM, D'Alessandro AM, et al. Indications for enteric conversion after pancreas transplantation with bladder drainage. Surgery, 1992, 112(4): 842-846.
26.	Pirsch JD, Odorico JS, D, alessandro AM, et al. Posttransplant infec-tion in enteric versus bladder-drained simultaneous pancreas-kidney transplant recipients. Transplantation, 1998, 66(12): 1746-1750.
27.	Philosophe B, Farney AC, Schweitzer EJ, et al. Superiority of portal venous drainage over systemic venous drainage in pancreas transp-lantation: a retrospective study. Ann Surg, 2001, 234(5): 689-696.
28.	李永胜, 李璐璐, 黄玉川, 等.门静脉回流与体静脉回流对胰肾联合移植效果影响的系统评价.中国循证医学杂志, 2008, 8(5): 358-363.
29.	Sutherland DE, Sibley R, Xu XZ, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of typeⅠdiabetes. Trans Assoc Am Physicians, 1984, 97: 80-87.
30.	Gruessner RW, Dunn DL, Tzardis PJ, et al. Simultaneous pancreas and kidney transplants versus single kidney transplants and previous kidney transplants in uremic patients and single pancreas transplants in nonuremic diabetic patients: comparison of rejection, morbidity, and long-term outcome. Transplant Proc, 1990, 22(2): 622-623.
31.	Guessner AC, Sutherland DE. Analysis of United States(US) and none-US pancreas transplants reported to the United Network for Organ Sharing(UNOS) and the International Pancreas Transplant Registry(IPTR) as of October 2001. Clin Transpl, 2001: 41-72.
32.	Lo A, Stratta RJ, Alloway RR, et al. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transpl Int, 2001, 14(6): 396-404.
33.	Kaufman DB, Iii GW, Bruce DS, et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant, 2003, 3(7): 855-864.
34.	Kaufman DB, Leventhal JR, Gallon LG, et al. Alemtuzumab induc-tion and prednisone-free maintenance immunotherapy in simul-taneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction-Long-term results. Am J Transplant, 2006, 6(2): 331-339.
35.	Stratta RJ, Rogers J, Orlando G, et al. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation. Transplant Proc, 2014, 46(6): 1928-1931.
36.	Niederhaus SV, Kaufman DB, Odorico JS. Induction therapy in pancreas transplantation. Transpl Int, 2013, 26(7): 704-714.
37.	Mittal S, Johnson P, Friend P. Pancreas transplantation: solid organ and islet. Cold Spring Harb Perspect Med, 2014, 4(4): a015610.
38.	Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med, 2003, 349(24): 2326-2333.
39.	Scalea JR, Butler CC, Munivenkatappa RB, et al. Pancreas transplant alone as an independent risk factor for the development of renal failure: a retrospective study. Transplantation, 2008, 86(12): 1789-1794.
40.	Wojciechowski D, Vincenti F. Belatacept in kidney transplantation. Curr Opin Organ Transplant, 2012, 17(6): 640-647.
41.	Mulgaonkar S, Kaufman DB. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients. Clin Transplant, 2014, 28(11): 1209-1224.
42.	Sutherland D, Gruessner AC. Long-term results after pancreas transplantation. Transplant Proc, 2007, 39(7): 2323-2325.
43.	Humar A, Parr E, Drangstveit MB, et al. Steroid withdrawal in pancreas transplant recipients. Clin Transplant, 2000, 14(1): 75-78.
44.	Gruessner RW, Sutherland DE, Parr E, et al. A prospective, rando-mized, open-label study of steroid withdrawal in pancreas transplan-tation-a preliminary report with 6-month follow-up. Transplant Proc, 2001, 33(1-2): 1663-1664.
45.	Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppre-ssion protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation, 2002, 73(2): 169-177.
46.	Montero N, Webster AC, Royuela A, et al. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recip-ients. Cochrane Database Syst Rev, 2014, 9: CD007669.
47.	Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of imm-unosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol, 2000, 11(10): 1910-1917.
48.	White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet, 2009, 373(9677): 1808-1817.
49.	Dong M, Parsaik AK, Kremers W, et al. Acute pancreas allograft rejection is associated with increased risk of graft failure in pancreas transplantation. Am J Transplant, 2013, 13(4): 1019-1025.
50.	Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibo-dies adversely affect kidney allograft outcomes. J Am Soc Nephrol, 2012, 23(12): 2061-2071.
51.	Redfield RR, Scalea JR, Odorico JS. Simultaneous pancreas and kidney transplantation: current trends and future directions. Curr Opin Organ Transplant, 2015, 20(1): 94-102.
52.	Desvaux D, Schwarzinger M, Pastural M, et al. Molecular diagnosis of renal-allograft rejection: correlation with histopathologic evaluation and antirejection-therapy resistance. Transplantation, 2004, 78(5): 647-653.
53.	Sutton VR, Waterhouse NJ, Browne KA, et al. Residual active granzyme B in cathepsin C-null lymphocytes is sufficient for perforin-dependent target cell apoptosis. J Cell Biol, 2007, 176(4): 425-433.
54.	Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation, 2013, 95(3): 410-417.
55.	Wiebe C, Nickerson P. Posttransplant monitoring of de novo humanleukocyte antigen donor-specific antibodies in kidney transplanta-tion. Curr Opin Organ Transplant, 2013, 18(4): 470-477.
56.	Caro-Oleas JL, González-Escribano MF, Gentil-Govantes MA, et al. Influence of donor specific HLA antibodies detected by Luminex in kidney graft survival: a multivariate analysis. Hum Immunol, 2013, 74(5): 545-549.
57.	Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibo-dies adversely affect kidney allograft outcomes. J Am Soc Nephrol, 2012, 23(12): 2061-2071.
58.	Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant, 2011, 11(2): 312-319.
59.	Ho EK, Vlad G, Vasilescu ER, et al. Pre-and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol, 2011, 72(1): 5-10.
60.	O'Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant, 18(3): 279-284.
61.	Kaneku H, O, leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transp-lant recipients. Am J Transplant, 2013, 13(6): 1541-1548.
62.	Mittal S, Page SL, Friend PJ, et al. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure. Am J Transplant, 2014, 14(7): 1664-1671.
63.	Sasaki TM, Gray RS, Ratner RE, et al. Successful long-term kidney-pancreas transplants in diabetic patients with high C-peptide levels. Transplantation, 1998, 65(11): 1510-1512.
64.	Light JA, Barhyte DY. Simultaneous pancreas-kidney transplants in typeⅠand typeⅡdiabetic patients with end-stage renal disease: similar 10-year outcomes. Transplant Proc, 2005, 37(2): 1283-1284.
65.	Light J, Tucker M. Simultaneous pancreas kidney transplants in diabetic patients with end-stage renal disease: the 20-yr experience. Clin Transplant, 2013, 27(3): E256-E263.
66.	Ciancio G, Burke GW. Type 2 diabetes: is pancreas transplantation an option? Curr Diabet Rep, 2014, 14(11): 542.
67.	Cohen DJ, Ratner LE. Type 2 diabetes: the best transplant option is still uncertain. Clin J Am Soc Nephrol, 2012, 7(4): 530-532.
68.	Siskind E, Maloney C, Akerman M, et al. An analysis of pancreas transplantation outcomes based on age groupings: an update of the UNOS database. Clin Transplant, 2014, 28: 990-994.
69.	McCullough KP, Keith DS, Meyer KH, et al. Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease. Am J Transplant, 2009, 9(4 Pt 2): 894-906.
70.	Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol, 2001, 12(6): 1293-1296.
71.	Ziaja J, Chudek J, Kolonko A, et al. Does simultaneously transp-lanted pancreas improve long-term outcome of kidney transplan-tation in type 1 diabetic recipients? Transplant Proc, 2011, 43(8): 3097-3101.
72.	Gross CR, Limwattananon C, Matthees BJ. Quality of life after pancreas transplantation: a review. Clin Transplant, 1998, 12(4): 351-361.
73.	Matas AJ, Mchugh L, Payne WD, et al. Long-term quality of life after kidney and simultaneous pancreas-kidney transplantation. Clin Transplant, 1998, 12(3): 233-242.
74.	Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA, 1993, 270(11): 1339-1343.
75.	Smets YF, Westendorp RG, Van Der Pijl JW, et al. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet, 1999, 353(9168): 1915-1919.
76.	Rayhill SC, D'Alessandro AM, Odorico JS, et al. Simultaneous pancreas-kidney transplantation and living related donor renal transplantation in patients with diabetes: is there a difference in survival? Ann Surg, 2000, 231(3): 417-423.
77.	Smith GC, Trauer T, Kerr PG, et al. Prospective quality-of-life monitoring of simultaneous pancreas and kidney transplant recipients using the 36-item short form health survey. Am J Kidney Dis, 2010, 55(4): 698-707.
78.	Gerber PA, Pavlicek V, Demartines N, et al. Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia, 2008, 51(1): 110-119.
79.	Robertson RP, Sutherland DE, Kendall DM, et al. Metabolic charac-terization of long-term successful pancreas transplants in typeⅠdiabetes. J Investig Med, 1996, 44(9): 549-555.
80.	Diem P, Redmon JB, Abid M, et al. Glucagon, catecholamine and pancreatic polypeptide secretion in typeⅠdiabetic recipients of pancreas allografts. J Clin Invest, 1990, 86(6): 2008-2013.
81.	Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes, 2001, 50(4): 710-719.
82.	Kendall DM, Teuscher AU, Robertson RP. Defective glucagon secretion during sustained hypoglycemia following successful islet allo-and autotransplantation in humans. Diabetes, 1997, 46(1): 23-27.
83.	Kendall DM, Rooney DP, Smets YF, et al. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing typeⅠdiabetes and autonomic neuropathy. Diabetes, 1997, 46(2): 249-257.
84.	Battezzati A, Bonfatti D, Benedini S, et al. Spontaneous hypogly-caemia after pancreas transplantation in type 1 diabetes mellitus. Diabet Med, 1998, 15(12): 991-996.
85.	Barrou Z, Seaquist ER, Robertson RP. Pancreas transplantation in diabetic humans normalizes hepatic glucose production during hypoglycemia. Diabetes, 1994, 43(5): 661-666.
86.	Hughes TA, Gaber AO, Amiri HS, et al. Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation. Metabolism, 1994, 43(3): 333-347.
87.	Luzi L, Battezzati A, Perseghin G, et al. Combined pancreas and kidney transplantation normalizes protein metabolism in insulin-dependent diabetic-uremic patients. J Clin Invest, 1994, 93(5): 1948-1958.
88.	Biesenbach G, Königsrainer A, Gross C, et al. Progression of macro-vascular diseases is reduced in type 1 diabetic patients after more than 5 years successful combined pancreas-kidney transplantation in comparison to kidney transplantation alone. Transpl Int, 2005, 18(9): 1054-1060.
89.	Larsen JL, Colling CW, Ratanasuwan T, et al. Pancreas transplan-tation improves vascular disease in patients with type 1 diabetes. Diabetes Care, 2004, 27(7): 1706-1711.
90.	Nankivell BJ, Lau SG, Chapman JR, et al. Progression of macrovascular disease after transplantation. Transplantation, 2000, 69(4): 574-811.
91.	Gliedman ML, Tellis VA, Soberman R, et al. Long-term effects of pancreatic transplant function in patients with advanced juvenile-onset diabetes. Diabetes Care, 1981, 1(1): 1-9.
92.	Bruce DS, Newell KA, Josephson MA, et al. Long-term outcome of kidney-pancreas transplant recipients with good graft function at one year. Transplantation, 1996, 62(4): 451-456.
93.	Woeste G, Wullstein C, Pridöhl O, et al. Incidence of minor and major amputations after pancreas/kidney transplantation. Transpl Int, 2003, 16(2): 128-132.
94.	Kennedy WR, Navarro X, Goetz FC, et al. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med, 1990, 322(15): 1031-1037.
95.	Martinenghi S, Comi G, Galardi G, et al. Amelioration of nerve conduction velocity following simultaneous kidney/pancreas transplantation is due to the glycaemic control provided by the pancreas.Diabetologia, 1997, 40(9): 1110-1112.
96.	Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med, 1998, 339(2): 69-75.
97.	Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy.Ⅲ. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol, 1984, 102(4): 527-532.
98.	Pai RP, Mitchell P, Chow VC, et al. Posttransplant cataract: lessons from kidney-pancreas transplantation. Transplantation, 2000, 69(6): 1108-1114.
99.	Antonetti DA, Barber AJ, Bronson SK, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes, 2006, 55(9): 2401-2411.

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329(14): 977-986.
2. Gross JL, De Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care, 2005, 28(1): 164-176.
3. Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery, 1967, 61(6): 827-837.
4. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival proba-bilities for dialysis patients vs cadaveric renal transplant recipients. JAMA, 1993, 270(11): 1339-1343.
5. Lindahl JP, Hartmann A, Horneland R, et al. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease. Diabetologia, 2013, 56(6): 1364-1371.
6. Sollinger HW, Odorico JS, Becker YT, et al. One thousand simul-taneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg, 2009, 250: 618-630.
7. Stratta RJ, Shokouh-Amiri MH, Egidi MF, et al. Long-term experi-ence with simultaneous kidney-pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetil-based immunosuppression. Clin Transplant, 2003, 17 Suppl 9: 69-77.
8. Kandaswamy R, Stock PG, Skeans MA, et al. OPTN/SRTR 2011 Annual Data Report: pancreas. Am J Transplant, 2013, 13 Suppl 1: 47-72.
9. Gruessner AC. 2011 update on pancreas transplantation: compreh-ensive trend analysis of 25 000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry(IPTR). Rev Diabet Stud, 2011, 8(1): 6-16.
10. Stratta RJ. Mortality after vascularized pancreas transplantation. Surgery, 1998, 124(4): 823-830.
11. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States(US) and non-US cases as reported to the United Network for Organ Sharing(UNOS) and the International Pancreas Transplant Registry(IPTR) as of June 2004. Clin Transplant, 2005, 19(4): 433-455.
12. Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1 000 pancreas transplants at a single institution. Ann Surg, 2001, 233(4): 463-501.
13. American Diabetes Association. Pancreas transplantation for patients with type 1 diabetes. Diabetes Care, 2000, 23(1): 117.
14. Fourtounas C. Transplant options for patients with type 2 diabetes and chronic kidney disease. World J Transplant, 2014, 4(2): 102-110.
15. Israni AK, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2012 annual data report: pancreas. Am J Transplant, 2014, 14(Suppl 1): 45-68.
16. Becker BN, Becker YT, Odorico JS, et al. Simultaneous pancreas-kidney and pancreas transplantation. Minerva Urol Nefrol, 2002, 54(4): 213-226.
17. Schulz T, Schenker P, Flecken M, et al. Donors with a maximum body weight of 50 kg for simultaneous pancreas-kidney transplanta-tion. Transplant Proc, 2005, 37(2): 1268-1270.
18. Gores PF, Gillingham KJ, Dunn DL, et al. Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience. Ann Surg, 1992, 215(3): 217-230.
19. Knight RJ, Bodian C, Rodriguez-Laiz G, et al. Risk factors for intra-abdominal infection after pancreas transplantation. Am J Surg, 2000, 179(2): 99-102.
20. Gruessner RW. Crossmatch positivity and ABO incompatibility//Gruessner RW, Sutherland DE, eds. Transplantation of the pancreas. New York: Springer, 2004: 398-403.
21. Odorico JS, Voss B, Munoz Del Rio A, et al. Kidney function after solitary pancreas transplantation. Transplant Proc, 2008, 40(2): 513-515.
22. Sollinger HW, Cook K, Kamps D, et al. Clinical and experimental experience with pancreaticocystostomy for exocrine pancreatic drainage in pancreas transplantation. Transplant Proc, 1984, 16(3): 749-751.
23. Black PC, Plaskon LA, Miller J, et al. Cystoenteric conversion and reduction cystoplasty for treatment of bladder dysfunction after pancreas transplantation. J Urol, 2003, 170(5): 1913-1917.
24. Sollinger HW, Odorico JS, Knechtle SJ, et al. Experience with 500 simultaneous pancreas-kidney transplants. Ann Surg, 1998, 228(3): 284-296.
25. Sollinger HW, Sasaki TM, D'Alessandro AM, et al. Indications for enteric conversion after pancreas transplantation with bladder drainage. Surgery, 1992, 112(4): 842-846.
26. Pirsch JD, Odorico JS, D, alessandro AM, et al. Posttransplant infec-tion in enteric versus bladder-drained simultaneous pancreas-kidney transplant recipients. Transplantation, 1998, 66(12): 1746-1750.
27. Philosophe B, Farney AC, Schweitzer EJ, et al. Superiority of portal venous drainage over systemic venous drainage in pancreas transp-lantation: a retrospective study. Ann Surg, 2001, 234(5): 689-696.
28. 李永胜, 李璐璐, 黄玉川, 等.门静脉回流与体静脉回流对胰肾联合移植效果影响的系统评价.中国循证医学杂志, 2008, 8(5): 358-363.
29. Sutherland DE, Sibley R, Xu XZ, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of typeⅠdiabetes. Trans Assoc Am Physicians, 1984, 97: 80-87.
30. Gruessner RW, Dunn DL, Tzardis PJ, et al. Simultaneous pancreas and kidney transplants versus single kidney transplants and previous kidney transplants in uremic patients and single pancreas transplants in nonuremic diabetic patients: comparison of rejection, morbidity, and long-term outcome. Transplant Proc, 1990, 22(2): 622-623.
31. Guessner AC, Sutherland DE. Analysis of United States(US) and none-US pancreas transplants reported to the United Network for Organ Sharing(UNOS) and the International Pancreas Transplant Registry(IPTR) as of October 2001. Clin Transpl, 2001: 41-72.
32. Lo A, Stratta RJ, Alloway RR, et al. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transpl Int, 2001, 14(6): 396-404.
33. Kaufman DB, Iii GW, Bruce DS, et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant, 2003, 3(7): 855-864.
34. Kaufman DB, Leventhal JR, Gallon LG, et al. Alemtuzumab induc-tion and prednisone-free maintenance immunotherapy in simul-taneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction-Long-term results. Am J Transplant, 2006, 6(2): 331-339.
35. Stratta RJ, Rogers J, Orlando G, et al. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation. Transplant Proc, 2014, 46(6): 1928-1931.
36. Niederhaus SV, Kaufman DB, Odorico JS. Induction therapy in pancreas transplantation. Transpl Int, 2013, 26(7): 704-714.
37. Mittal S, Johnson P, Friend P. Pancreas transplantation: solid organ and islet. Cold Spring Harb Perspect Med, 2014, 4(4): a015610.
38. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med, 2003, 349(24): 2326-2333.
39. Scalea JR, Butler CC, Munivenkatappa RB, et al. Pancreas transplant alone as an independent risk factor for the development of renal failure: a retrospective study. Transplantation, 2008, 86(12): 1789-1794.
40. Wojciechowski D, Vincenti F. Belatacept in kidney transplantation. Curr Opin Organ Transplant, 2012, 17(6): 640-647.
41. Mulgaonkar S, Kaufman DB. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients. Clin Transplant, 2014, 28(11): 1209-1224.
42. Sutherland D, Gruessner AC. Long-term results after pancreas transplantation. Transplant Proc, 2007, 39(7): 2323-2325.
43. Humar A, Parr E, Drangstveit MB, et al. Steroid withdrawal in pancreas transplant recipients. Clin Transplant, 2000, 14(1): 75-78.
44. Gruessner RW, Sutherland DE, Parr E, et al. A prospective, rando-mized, open-label study of steroid withdrawal in pancreas transplan-tation-a preliminary report with 6-month follow-up. Transplant Proc, 2001, 33(1-2): 1663-1664.
45. Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppre-ssion protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation, 2002, 73(2): 169-177.
46. Montero N, Webster AC, Royuela A, et al. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recip-ients. Cochrane Database Syst Rev, 2014, 9: CD007669.
47. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of imm-unosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol, 2000, 11(10): 1910-1917.
48. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet, 2009, 373(9677): 1808-1817.
49. Dong M, Parsaik AK, Kremers W, et al. Acute pancreas allograft rejection is associated with increased risk of graft failure in pancreas transplantation. Am J Transplant, 2013, 13(4): 1019-1025.
50. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibo-dies adversely affect kidney allograft outcomes. J Am Soc Nephrol, 2012, 23(12): 2061-2071.
51. Redfield RR, Scalea JR, Odorico JS. Simultaneous pancreas and kidney transplantation: current trends and future directions. Curr Opin Organ Transplant, 2015, 20(1): 94-102.
52. Desvaux D, Schwarzinger M, Pastural M, et al. Molecular diagnosis of renal-allograft rejection: correlation with histopathologic evaluation and antirejection-therapy resistance. Transplantation, 2004, 78(5): 647-653.
53. Sutton VR, Waterhouse NJ, Browne KA, et al. Residual active granzyme B in cathepsin C-null lymphocytes is sufficient for perforin-dependent target cell apoptosis. J Cell Biol, 2007, 176(4): 425-433.
54. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation, 2013, 95(3): 410-417.
55. Wiebe C, Nickerson P. Posttransplant monitoring of de novo humanleukocyte antigen donor-specific antibodies in kidney transplanta-tion. Curr Opin Organ Transplant, 2013, 18(4): 470-477.
56. Caro-Oleas JL, González-Escribano MF, Gentil-Govantes MA, et al. Influence of donor specific HLA antibodies detected by Luminex in kidney graft survival: a multivariate analysis. Hum Immunol, 2013, 74(5): 545-549.
57. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibo-dies adversely affect kidney allograft outcomes. J Am Soc Nephrol, 2012, 23(12): 2061-2071.
58. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant, 2011, 11(2): 312-319.
59. Ho EK, Vlad G, Vasilescu ER, et al. Pre-and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol, 2011, 72(1): 5-10.
60. O'Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant, 18(3): 279-284.
61. Kaneku H, O, leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transp-lant recipients. Am J Transplant, 2013, 13(6): 1541-1548.
62. Mittal S, Page SL, Friend PJ, et al. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure. Am J Transplant, 2014, 14(7): 1664-1671.
63. Sasaki TM, Gray RS, Ratner RE, et al. Successful long-term kidney-pancreas transplants in diabetic patients with high C-peptide levels. Transplantation, 1998, 65(11): 1510-1512.
64. Light JA, Barhyte DY. Simultaneous pancreas-kidney transplants in typeⅠand typeⅡdiabetic patients with end-stage renal disease: similar 10-year outcomes. Transplant Proc, 2005, 37(2): 1283-1284.
65. Light J, Tucker M. Simultaneous pancreas kidney transplants in diabetic patients with end-stage renal disease: the 20-yr experience. Clin Transplant, 2013, 27(3): E256-E263.
66. Ciancio G, Burke GW. Type 2 diabetes: is pancreas transplantation an option? Curr Diabet Rep, 2014, 14(11): 542.
67. Cohen DJ, Ratner LE. Type 2 diabetes: the best transplant option is still uncertain. Clin J Am Soc Nephrol, 2012, 7(4): 530-532.
68. Siskind E, Maloney C, Akerman M, et al. An analysis of pancreas transplantation outcomes based on age groupings: an update of the UNOS database. Clin Transplant, 2014, 28: 990-994.
69. McCullough KP, Keith DS, Meyer KH, et al. Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease. Am J Transplant, 2009, 9(4 Pt 2): 894-906.
70. Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol, 2001, 12(6): 1293-1296.
71. Ziaja J, Chudek J, Kolonko A, et al. Does simultaneously transp-lanted pancreas improve long-term outcome of kidney transplan-tation in type 1 diabetic recipients? Transplant Proc, 2011, 43(8): 3097-3101.
72. Gross CR, Limwattananon C, Matthees BJ. Quality of life after pancreas transplantation: a review. Clin Transplant, 1998, 12(4): 351-361.
73. Matas AJ, Mchugh L, Payne WD, et al. Long-term quality of life after kidney and simultaneous pancreas-kidney transplantation. Clin Transplant, 1998, 12(3): 233-242.
74. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA, 1993, 270(11): 1339-1343.
75. Smets YF, Westendorp RG, Van Der Pijl JW, et al. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet, 1999, 353(9168): 1915-1919.
76. Rayhill SC, D'Alessandro AM, Odorico JS, et al. Simultaneous pancreas-kidney transplantation and living related donor renal transplantation in patients with diabetes: is there a difference in survival? Ann Surg, 2000, 231(3): 417-423.
77. Smith GC, Trauer T, Kerr PG, et al. Prospective quality-of-life monitoring of simultaneous pancreas and kidney transplant recipients using the 36-item short form health survey. Am J Kidney Dis, 2010, 55(4): 698-707.
78. Gerber PA, Pavlicek V, Demartines N, et al. Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia, 2008, 51(1): 110-119.
79. Robertson RP, Sutherland DE, Kendall DM, et al. Metabolic charac-terization of long-term successful pancreas transplants in typeⅠdiabetes. J Investig Med, 1996, 44(9): 549-555.
80. Diem P, Redmon JB, Abid M, et al. Glucagon, catecholamine and pancreatic polypeptide secretion in typeⅠdiabetic recipients of pancreas allografts. J Clin Invest, 1990, 86(6): 2008-2013.
81. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes, 2001, 50(4): 710-719.
82. Kendall DM, Teuscher AU, Robertson RP. Defective glucagon secretion during sustained hypoglycemia following successful islet allo-and autotransplantation in humans. Diabetes, 1997, 46(1): 23-27.
83. Kendall DM, Rooney DP, Smets YF, et al. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing typeⅠdiabetes and autonomic neuropathy. Diabetes, 1997, 46(2): 249-257.
84. Battezzati A, Bonfatti D, Benedini S, et al. Spontaneous hypogly-caemia after pancreas transplantation in type 1 diabetes mellitus. Diabet Med, 1998, 15(12): 991-996.
85. Barrou Z, Seaquist ER, Robertson RP. Pancreas transplantation in diabetic humans normalizes hepatic glucose production during hypoglycemia. Diabetes, 1994, 43(5): 661-666.
86. Hughes TA, Gaber AO, Amiri HS, et al. Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation. Metabolism, 1994, 43(3): 333-347.
87. Luzi L, Battezzati A, Perseghin G, et al. Combined pancreas and kidney transplantation normalizes protein metabolism in insulin-dependent diabetic-uremic patients. J Clin Invest, 1994, 93(5): 1948-1958.
88. Biesenbach G, Königsrainer A, Gross C, et al. Progression of macro-vascular diseases is reduced in type 1 diabetic patients after more than 5 years successful combined pancreas-kidney transplantation in comparison to kidney transplantation alone. Transpl Int, 2005, 18(9): 1054-1060.
89. Larsen JL, Colling CW, Ratanasuwan T, et al. Pancreas transplan-tation improves vascular disease in patients with type 1 diabetes. Diabetes Care, 2004, 27(7): 1706-1711.
90. Nankivell BJ, Lau SG, Chapman JR, et al. Progression of macrovascular disease after transplantation. Transplantation, 2000, 69(4): 574-811.
91. Gliedman ML, Tellis VA, Soberman R, et al. Long-term effects of pancreatic transplant function in patients with advanced juvenile-onset diabetes. Diabetes Care, 1981, 1(1): 1-9.
92. Bruce DS, Newell KA, Josephson MA, et al. Long-term outcome of kidney-pancreas transplant recipients with good graft function at one year. Transplantation, 1996, 62(4): 451-456.
93. Woeste G, Wullstein C, Pridöhl O, et al. Incidence of minor and major amputations after pancreas/kidney transplantation. Transpl Int, 2003, 16(2): 128-132.
94. Kennedy WR, Navarro X, Goetz FC, et al. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med, 1990, 322(15): 1031-1037.
95. Martinenghi S, Comi G, Galardi G, et al. Amelioration of nerve conduction velocity following simultaneous kidney/pancreas transplantation is due to the glycaemic control provided by the pancreas.Diabetologia, 1997, 40(9): 1110-1112.
96. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med, 1998, 339(2): 69-75.
97. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy.Ⅲ. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol, 1984, 102(4): 527-532.
98. Pai RP, Mitchell P, Chow VC, et al. Posttransplant cataract: lessons from kidney-pancreas transplantation. Transplantation, 2000, 69(6): 1108-1114.
99. Antonetti DA, Barber AJ, Bronson SK, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes, 2006, 55(9): 2401-2411.

Previous Article
Research Progress of Pancreatic Fistula Following Pancreaticoduodenectomy
Next Article
Reviews of Exposure Technology of Gastroesophageal Region in Laparoscopic Surgery

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

History, Present Situation, and Prospect of Simultaneous Pancreas and Kidney Trans-plantation in Treatment of Diabetes

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content